ClinicalTrials.gg
RecruitingNCT07222787ILIFUpdated Sep 16, 2026

Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes

An interventional study of Supplemental Posterior Fusion with Study Device and Supplemental Posterior Fusion with Standard Technique in Radiculopathy Lumbar and Degenerative Lumbar Disc Disease, sponsored by Providence Medical Technology, Inc.. Recruiting at 12 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Providence Medical Technology, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Radiculopathy with a site in United States — 30 open to participants now, 38 under way, 2 of them phase 3. Radiculopathy · United States.

Planned enrollment
15th of 106
250 · median 78
Started
2025
with 3 others
No phase
63 of 127
17 open now
Primary completion
2028-07
later than 34 of 37 live
Registered
118th of 127
by date
Lead sponsor
5 of 127
Providence Medical Technology, Inc.

Among the 127 studies in Radiculopathy with a site in United States, this one is the 15th largest by planned enrollment of the 106 interventional ones that give a count, is one of 4 that started in 2025, is one of 63 with no phase, reaches primary completion later than 34 of the 37 other live ones, and was the 118th registered.

Radiculopathy

488 studies on the registry are indexed under Radiculopathy; 145 are open to participants now.

Browse Radiculopathy studies →

Open to participants now

30 of the 127 studies in Radiculopathy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Radiculopathy with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the safety and effectiveness of the study device, CORUS-LX, as an adjunct to lumbar interbody fusion, when used in combination with pedicle screw and rod constructs for the treatment of lumbosacral degenerative disease in patients requiring 2 level (L4-S1) lumbar fusion, for the treatment of symptomatic degenerative lumbosacral disc disease. The main questions it aims to answer are:

Is there fusion success at the treated posterior anatomy of each level? Is there an absence of major adverse device related events? Is there an absence of injections (steroid, facet joint, nerve block) or subsequent revision surgery at index levels for symptoms related to back or leg pain?

Researchers will compare a control arm to the treatment arm to see if research results vary from standard minimally invasive supplemental posterior fusion.

Eligible participants will undergo one of the below interventions:

  • Two-level lumbar interbody fusion at L4-L5 \& L5-S1 segments, with supplemental posterior fusion performed using the study device, including pedicle screw and rod fixation.
  • Two-level lumbar interbody fusion at L4-L5 \& L5-S1 segments, with standard minimally invasive supplemental posterior fusion including pedicle screw and rod fixation.

Participants will also be asked to read, understand, and sign the informed consent, attend a Screening/Baseline visit, undergo surgery for their designated intervention, and participate in 5 additional study visits where they will complete surveys for patient reported outcomes and SOC procedures. These visits will occur at the below intervals (based upon surgery day as day 0):

  • 6 weeks
  • 3 months
  • 6 months
  • 12 months
  • 24 months
Read the detailed description

The study device is designed to provide surgeons a tissue-sparing solution for both preparing a fusion bed around the facet space in addition to stabilizing the joint in sync with percutaneous pedicle screw and rod fixation. There have been few rigorous studies looking at the posterior fusion aspect of circumferential lumbar fusion. Through a randomized controlled trial design and multi-modal imaging protocol, we aim to explore whether the opportunity for improved outcomes exists.

This randomized controlled trial was designed to compare outcomes in subjects treated with interbody fusion including supplemental posterior fusion for the treatment of degenerative lumbosacral disease. For the control arm subjects, supplemental posterior fusion will be performed with each surgeon's standard protocol for fusion with pedicle screw and rods. Treatment arm subjects will also receive percutaneous pedicle screw fixation but will also have the posterior anatomy prepared for fusion using the study device. In both arms, all posterior instrumentation will be placed using navigation technology. Study success will be defined as the demonstration of statistical superiority by the treatment arm over the control arm with respect to the primary endpoint, which is the incidence of arthrodesis achieved across the posterior anatomy. Additional data of interest will be collected to explore relationships between observed arthrodesis rates at the posterior anatomy and the rates of arthrodesis across the interbody space, serious device-related adverse events, device failure, subsequent surgical revisions, patient-reported outcomes, and return-to-work measures assessed through 24 months. Eligible subjects will be those with degenerative lumbosacral disease diagnosed at 2 levels between the L4 and S1 segments who are indicated for treatment using an interbody fusion approach supplemented with posterior fusion including pedicle screw and rod fixation. Major exclusionary factors will be history of prior instrumentation at the index or adjacent levels, fused facet or facet hypertrophy that prohibits device implantation, and a diagnosis of osteoporosis.

03

Conditions studied

  • Radiculopathy Lumbar
  • Degenerative Lumbar Disc Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years (Skeletally Mature)
  2. Indicated for lumbar interbody fusion for treatment of degenerative lumbosacral disease at two contiguous disc levels between L4-S1 as determined by the following:

    a) Diagnosis of radiculopathy of the lumbar spine, with pain, including at least one of the following: i) Leg and/or buttock pain, weakness, numbness, or paresthesia ii) Low back pain iii) Neurogenic claudication b) Radiographically determined pathology (CT, MRI, X-rays) at the levels to be treated correlating to primary symptoms including at least one of the following: i) Decreased disc height in comparison to a normal adjacent disc. ii) Degenerative instability ≤ grade 1 spondylolisthesis (\<25% slip). iii) Recurrent disc herniation. iv) Central and/or foraminal stenosis.

  3. Oswestry Disability Index Score of > 40/100 (Severe Disability).
  4. Unresponsive to non-operative, conservative treatment (rest, heat, electrotherapy, physical therapy, chiropractic care and/or analgesics) for:

    1. At least six weeks from symptom onset; or
    2. Have the presence of progressive symptoms or signs of nerve root/ spinal cord compression despite continued non-operative conservative treatment.
  5. Reported to be medically cleared for surgery.
  6. Physically and mentally able and willing to comply with the Protocol, including the ability to read and complete required forms
  7. Willing and able to adhere to the scheduled follow-up visits and requirements of the Protocol.
  8. Written provided by subject.

Exclusion criteria

Exclusion Criteria:

  1. Any disease or condition that, in the investigator's opinion, would preclude accurate radiographic evaluation of any treated vertebrae (e.g. morbid obesity).
  2. Any anatomy or condition that makes posterior fusion treatment infeasible (e.g. fused facets).
  3. Has, in the Investigator's opinion, any disease or condition that would preclude accurate clinical evaluation (e.g. neuromuscular disorders).
  4. Active systemic infection or infection at the operative site.
  5. Anticipated treatment for active systemic infection, including or .
  6. Previous trauma to any of the L3 to S1 levels resulting in significant bony or disco-ligamentous lumbar spine injury that may prevent device placements.
  7. Prior instrumented surgery or pseudoarthrosis at the operative or adjacent levels.
  8. Indicated for or history of laminectomy at any of the index or adjacent levels
  9. Fixed or permanent neurologic deficit related to the target treatment levels that cannot be improved with surgery
  10. Leg, buttocks, or back pain in the absence of other symptoms of radiculopathy or myeloradiculopathy justifying the need for surgical intervention.
  11. Symptomatic disc degeneration requiring surgical intervention at more or less than two levels.
  12. Diagnosis of spondylolisthesis, grade >1.
  13. Diagnosis of lytic spondylolisthesis
  14. Diagnosis of iatrogenic, traumatic, or dysplastic spondylolisthesis
  15. Congenital bony and/or spinal cord abnormalities affecting spinal stability.
  16. Diagnosis of Paget's disease, osteomalacia or any other metabolic bone disease other than osteopenia.
  17. Diagnosis of osteoporosis, defined as a previous DEXA bone density T-score of ≤-2.5.
  18. Active or a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and without clinical signs or symptoms of the malignancy for at least five years.
  19. Has an uncontrolled seizure disorder.
  20. Cauda equina syndrome or neurogenic bowel/bladder dysfunction;
  21. Use of epidural within 14 days prior to surgery.
  22. A concomitant condition requiring daily, high-dose oral steroids.

    High dose steroid use is defined as:

    1. Daily, chronic use of oral steroids of 5 mg/day or greater (steroid inhalers are not exclusionary).
    2. Use of short-term (less than 10 days) oral steroids at a daily dose greater than 40 mg within one month of the study procedure.
  23. Long-term use (>6 months) of opioids >120 mg morphine equivalents.
  24. Known allergy to titanium (Ti)
  25. A current or recent history (≤1 year prior to screening) of substance abuse that required medical treatment.
  26. Is pregnant, nursing, or interested in becoming pregnant within the next 3 years from the time of screening.
  27. Participation as a subject in any other clinical studies involving medical devices or drugs in the last 30 days prior to surgery
  28. A pending personal litigation relating to spinal injury (worker's compensation is not exclusionary).
  29. Anticipated or potential relocation greater than 50 miles that may interfere with completion of follow-up examinations.
  30. A mental illness or belongs to a vulnerable population, as determined by the investigator (e.g., prisoner or developmentally disabled), that would compromise ability to provide or compliance with follow-up requirements.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Standard Supplemental Posterior Fusion Technique

    Two-level lumbar interbody fusion at L4-L5 \& L5-S1 segments, with standard supplemental posterior fusion including pedicle screw and rod fixation.

    Device: Supplemental Posterior Fusion with Standard Technique

  • Experimental
    Supplemental Posterior Fusion with Study Device

    Two-level lumbar interbody fusion at L4-L5 \& L5-S1 segments, with supplemental posterior fusion performed using the study device, including pedicle screw and rod fixation.

    Device: Supplemental Posterior Fusion with Study Device

Interventions

  • DeviceSupplemental Posterior Fusion with Study Device

    Two-level lumbar interbody fusion at L4-L5 \& L5-S1 segments, with supplemental posterior fusion performed using the Study Device, including pedicle screw and rod fixation.

  • DeviceSupplemental Posterior Fusion with Standard Technique

    Two-level lumbar interbody fusion at L4-L5 \& L5-S1 segments, with standard minimally invasive supplemental posterior fusion including pedicle screw and rod fixation.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with fusion success at the treated posterior anatomy of each level.

    An individual subject is considered a fusion success if there is evidence of bridging trabecular bone across the posterior anatomy identified at both index levels determined using thin-slice CT and assessed by a third-party core imaging laboratory.

    Time frame: 12 months post procedure

  2. Proportion of participants with freedom from serious adverse event with definite relationship to treatment devices (interbody or posterior devices).

    The seriousness and relationship of each adverse event will be adjudicated by a clinical events committee. A subject will be considered a primary endpoint failure if an adverse event is determined by the committee to be serious and to have a relationship to any of the devices used in the procedure including both interbody and posterior devices.

    Time frame: 12 months post procedure

  3. Proportion of Participants with freedom from injections (steroid, facet joint, nerve block) or subsequent revision surgery at index levels for symptoms related to back or leg pain.

    A subject will be considered a primary endpoint failure if they require injections or subsequent revision surgery to treat new or recurrent symptoms of back or leg pain after their index surgery.

    Time frame: 12 months post procedure

Secondary outcomes

  1. Proportion of participants with the presence of Interbody bridging bone.

    An individual subject is considered a success if there is evidence of bridging trabecular bone across the interbody space identified at both index levels determined using thin-slice CT and assessed by a third-party core imaging laboratory.

    Time frame: 12 month visit

  2. Differences in average segmental range of motion of the treated levels

    Range of motion for each of the two treated levels will be measured by a third-party core imaging lab.

    Time frame: 12 month visit

  3. Differences in average change in disc height of the treated levels

    Change in disc height for each of the two treated levels will be measured between the week-6 and 12-month visits by a third-party core imaging lab.

    Time frame: 12 month visit

  4. Proportion of participants with freedom from injections (steroid, facet joint, nerve block) or subsequent revision surgery at treated levels for symptoms related to back or leg pain.

    A subject will be considered a failure for this endpoint if they require injections or subsequent revision surgery to treat new or recurrent symptoms of back or leg pain after their index surgery.

    Time frame: through 24 month visit

07

Study locations

10 of 12 sites recruiting
  • Barrow Brain & Spine
    Scottsdale, Arizona 85251, United States
    Recruiting
    • Helen Riahi, Clinical Research Coordinator · Contacthriahi@honorhealth.com · 480-583-0295
    • Bryan Lee, MD · Principal investigator
  • HonorHealth Neurology
    Scottsdale, Arizona 85251, United States
    Recruiting
    • Mattie Wheeler, Clinical Research Coordinator · Contactmawheeler@honorhealth.com · 480-534-4525
    • Abhineet Chowdhary, MD · Principal investigator
  • California Spine
    Los Angeles, California 90033, United States
    Recruiting
    • Inaara Bhola, Clinical Research Coordinator · Contactinaara@california-spine.com · 323-573-5116
    • Mohsin Fidai, MD · Principal investigator
  • Golden State Orthopedics & Spine
    Los Gatos, California 95032, United States
    Recruiting
  • Orthopaedic Spine Institute
    Hinsdale, Illinois 60521, United States
    Recruiting
    • Shanti Badra, Clinical Research Coordinator · Contactma@osiclinic.com · 630-381-1381
    • Vivek Mohan, MD · Principal investigator
  • Hospital for Special Surgery
    New York, New York 10021, United States
    Recruiting
    • Catherine Gang Clinical Research Coordinator · Contactgangh@hss.edu · 212-224-7980
    • Madison Myers Clinical Research Coordinator · Contactmyersm@hss.edu
    • James Dowdell, MD · Principal investigator
    • William Zelenty, MD · Sub investigator
  • Atlantic Brain and Spine
    Wilmington, North Carolina 28401, United States
    Recruiting
  • The Ohio State University
    Columbus, Ohio 43210, United States
    Recruiting
  • Olympia Neurological Institute
    Austin, Texas 78745, United States
    Not yet recruiting
  • Spine Physician Institute
    Dallas, Texas 75234, United States
    Terminated

    Not enrolling at this site.

  • American Neurospine Institute
    Frisco, Texas 75033, United States
    Recruiting
  • Huntsman Spine
    Salt Lake City, Utah 84124, United States
    Recruiting
    • Alex Reedy, Clinical Research Coordinator · Contactareedy@saon.net · 801-346-7788
    • Kade Huntsman, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Specific IPD will be shared on a case-by-case basis after review of proposals by the Sponsor and Investigators.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2028, 31 months after the start.

Of 217 interventional studies with no phase under Radiculopathy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 41. This study's planned 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2025
First posted
Oct 30, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2029
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07222787
Lead sponsor
Providence Medical Technology, Inc.
Responsible party
Sponsor
First posted
Oct 30, 2025
Start date
Dec 1, 2025
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Sep 16, 2026

Study contacts

Matt Jenkins
Contact
ILIF@providencemt.com
805-450-4965
Matt Jenkins
study director · Providence Medical Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion